357443-58-4Relevant academic research and scientific papers
PYRIDO PYRIMIDINES
-
, (2012/07/28)
Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists
Nguyen, Kevin T.,Claiborne, Christopher F.,McCauley, John A.,Libby, Brian E.,Claremon, David A.,Bednar, Rodney A.,Mosser, Scott D.,Gaul, Stanley L.,Connolly, Thomas M.,Condra, Cindra L.,Bednar, Bohumil,Stump, Gary L.,Lynch, Joseph J.,Koblan, Kenneth S.,Liverton, Nigel J.
, p. 3997 - 4000 (2008/02/10)
A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.
Novel phenylheteroalkylamine derivatives
-
, (2008/06/13)
There are provided novel compounds of formula (I), wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.
